three years of survodutide threads, summarised so you do not have to read them
three years of survodutide threads, summarised so you do not have to read them. Not a hot take, just something I have not seen said plainly here. Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of…
Push back: the evidence here is phase 2, in a specific population, and it does not support a general ranking.
[removed by moderator]
MASH endpoints are histological, which is a much harder bar
MASH endpoints are histological, which is a much harder bar
Disagreeing with this bit: that number comes from a different programme with a different population.
Disagree — that is a weight endpoint from a different programme and you are quoting it in a hepatic context.
That figure is from the obesity programme, and this thread is about the hepatic one.
fibrosis improvement without worsening steatohepatitis is the phrase to learn
Phase 2 in a biopsy-confirmed population is a demanding design: recruitment is slow, the population is specific, and the results do not generalise to people who have not been characterised that way.
a liver endpoint is not a weight endpoint with better marketing
Went slowly because everything published describes a deliberate escalation. That is the extent of what I will say about it.
biopsy-confirmed is not the same as imaging-suggested